Who are we?
Medison is Israel’s leading pharmaceutical partner, uniquely qualified to provide the entire spectrum of integrated services for international companies in Israel’s healthcare market. Employing a comprehensive approach to marketing and service, Medison supplies and maintains long-standing relations with HMOs (Health Maintenance Organizations), local medical centers and physicians.
Backed by three generations of experience in the healthcare industry since 1937, Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli and Romanian healthcare markets.
We work together with our partners to meet unmet medical
needs in a diverse range of therapeutic fields:
- Rare Diseases
- Palliative Care
Drugs Disributed by Medison Pharma Ltd
Thrombin Inhibitor. Bivalirudin 250 mg/vial. VIALS (pwdr. for I.V. inject.): 1 x 10. I.V.
bolus: 1.0 mg/kg foll. by 4 hr. infus. at
rate of 2.5 mg/kg/hr. Aft. complete
initial 4 hr. infus., addition. I.V. infus.
may be initiat. at 0.2 mg/kg/hr. for up
to 20 hrs. if reqd. Use with aspirin (300
- 325 mg dly). Initiate just prior to
PTCA. May need to reduce dose and
anticoag. status monitored in pts. with
Unstable ang. undergoing percutan.
translum. coron. angioplasty (PTCA). To
be used with aspirin. See lit. for safety
C/I: Known hypersens.
Immunomodulator. Interferon Beta-1a 30 mcg. PRE-FILL. SYR/PEN: 4.
SINGLE-USE VIAL: 4. 1 inject I.M. 1 x
wkly (self-inject. permitted).
Relapse form multiple sclerosis, slow
accumulation of physical disabil., decr.
freq. clinical exacerbations. Tmt. demyelinat. event with active inflamm.
process if severe enough to treat with I.V.
corticoster., if alt. diagn. excluded incl.
MRI abnorm. characters. of MS if at high
risk of develop. clin. defin. MS.
C/I: Hypersens. to natural or
recombinant interferon beta, human
albumin or any other component.
Perfluoropropane 1.1 mg/ml. VIALS: 2 ml. I.V. bolus/infus. See lit.
Echocard. of card. structures (ventric.
chambers, endocard. borders) function
(regional wall motion) in adult pts. with
suboptimal echocardiograms. Abdom.
ultrasound: Liver and kidneys in adult pts.
to improve evaluation of pathology.
C/I: Hypersens., pts. with card. shunts.
Antithrombotic Agent. Defibrotide 80 mg/ml. VIAL (Concentrat. for sol. for infus.): The recomm. dose is 6.25 mg/kg bdy wt. every 6 hrs. (25 mg/kg/d).
There is limited effic. and safet. data on doses above this level and consequen. it is not recom. to incr. the dose above 25 mg/kg/d.
The tmt. should be admin. for a min. of 21 d. and cont. until the sympt. and signs of sev. VOD resolve. See lit.
Tmt. of sev. hepat. veno-occlusive dis. (VOD) also known as sinusoid. obstruct. syndr. (SOS) in haematopoietic stem-cell transplantat. (HSCT) ther.
It is indicated in adult. and in adolesc., child. and infant. over 1 mnth. of age.
C/I: Hypersens. Concom. use of thrombolytic ther.